Table 2 Summary of safety events

From: Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study

 

Esaxerenone (n = 51)

At least one AE, n (%)

25 (49.0)

TEAEs reported in ≥3% of patients, n (%)

  Viral upper respiratory tract infection

10 (19.6)

  Increased serum K+

6 (11.8)

   Back pain

2 (3.9)

At least one drug-related AE, n (%)

4 (7.8)

  Thrombotic cerebral infarction

1 (2.0)

  Increased serum K+

3 (5.9)

Treatment discontinued due to an AE, n (%)

2 (3.9)

  Thrombotic cerebral infarction

1 (2.0)

  Rash generalized

1 (2.0)

Discontinuation due to increased serum K+

0 (0)

Dose reduction due to serum K+ ≥5.5 to <6.0 mEq/L on two consecutive measurements, n (%)

1 (2.0)

  1. AE adverse event, TEAE treatment-emergent adverse event
Back to article page